What is Zacks Research’s Forecast for Alkermes Q3 Earnings?

Alkermes plc (NASDAQ:ALKS) – Research analysts at Zacks Research decreased their Q3 2026 earnings per share estimates for shares of Alkermes in a research note issued on Wednesday, April 9th. Zacks Research analyst R. Department now forecasts that the company will earn $0.23 per share for the quarter, down from their previous estimate of $0.24. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q1 2027 earnings at $0.18 EPS.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

ALKS has been the topic of several other reports. UBS Group raised Alkermes from a “sell” rating to a “neutral” rating and increased their target price for the stock from $21.00 to $38.00 in a report on Tuesday, March 4th. HC Wainwright reissued a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a report on Thursday, February 13th. The Goldman Sachs Group boosted their target price on shares of Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Royal Bank of Canada assumed coverage on shares of Alkermes in a research report on Thursday, March 13th. They set a “sector perform” rating and a $40.00 price target on the stock. Finally, StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.50.

Alkermes Price Performance

Shares of NASDAQ:ALKS opened at $27.00 on Friday. The business’s 50 day simple moving average is $33.14 and its 200 day simple moving average is $30.45. Alkermes has a 1 year low of $22.90 and a 1 year high of $36.45. The company has a market capitalization of $4.45 billion, a P/E ratio of 12.44, a P/E/G ratio of 2.20 and a beta of 0.39.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 100,918 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the transaction, the executive vice president now owns 44,290 shares of the company’s stock, valued at $1,419,494.50. This represents a 69.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 4.89% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Private Client Services LLC acquired a new stake in Alkermes in the first quarter valued at approximately $929,000. GAMMA Investing LLC grew its position in Alkermes by 4,255.3% in the 1st quarter. GAMMA Investing LLC now owns 178,176 shares of the company’s stock valued at $5,396,000 after purchasing an additional 174,085 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Alkermes by 60.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,107 shares of the company’s stock valued at $463,000 after purchasing an additional 6,073 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Alkermes during the 4th quarter valued at $3,273,000. Finally, Mackenzie Financial Corp raised its holdings in Alkermes by 9.0% during the fourth quarter. Mackenzie Financial Corp now owns 332,626 shares of the company’s stock worth $9,566,000 after buying an additional 27,604 shares during the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.